Development of a novel therapy for melanoma that inhibits T cell suppressive molecules
Project/Area Number |
25461687
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | University of Yamanashi |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | メラノーマ / 免疫チェックポイント / TIGIT / CD155 / CD226 / CD271 / T cell抑制因子 / NGF |
Outline of Final Research Achievements |
Blocking antibody for T cell suppressive factors is an innovative melanoma therapy. In the previous study, we have identified 80 candidate molecules for novel T cell suppressive factors. Among them, we characterized some molecules that were useful as targets of melanoma therapy. We found that an inhibitory signal from CD155 on melanoma cells to TIGIT on T cells was selectively enhanced in the tumor environment. Also we have demonstrated that blocking antibody for TIGIT enhanced the anti-melanoma T cell response cooperatively with anti PD-1 antibody. Our data suggested the usefulness of anti-TIGIT blocking antibody as a novel melanoma therapy.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
-
-
-
-
[Presentation] 癌免疫療法の現状と課題2016
Author(s)
猪爪隆史
Organizer
東葛北部がん治療、支持療法フォーラム
Place of Presentation
柏の葉カンファレンスセンター、千葉県、柏市
Year and Date
2016-03-11
Related Report
Invited
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-